Effects of Glucagon-like Peptide-1 Receptor Agonists on Secretions of Insulin and Glucagon and Gastric Emptying in Japanese Individuals with Type 2 Diabetes: A Prospective, Observational Study

Overview

Journal J Diabetes Investig

Specialty Endocrinology

Date 2021 May 22

PMID 34022121

Citations 16

Authors

Hitoshi Kuwata

Daisuke Yabe

Kenta Murotani

Yuuka Fujiwara

Takuya Haraguchi

Sodai Kubota

Saki Kubota-Okamoto

Ryota Usui

Minori Ishitobi

Yuji Yamazaki

Yoshiyuki Hamamoto

Takeshi Kurose

Yusuke Seino

Yuichiro Yamada

Yutaka Seino

Affiliations

Soon will be listed here.

Abstract

Aims/introduction: Differences in the glucose-lowering mechanisms of glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been noted. Clarifying these differences could facilitate the choice of optimal drugs for individuals with type 2 diabetes and requires investigation in a clinical setting.

Materials And Methods: A single-arm, prospective, observational study was conducted to evaluate the effects of various GLP-1RAs on postprandial glucose excursion, secretions of insulin and glucagon as well as on the gastric emptying rate. Participants were subjected to meal tolerance tests before and 2 weeks and 12 weeks after GLP-1RA initiation. Effects on postprandial secretions of glucose-dependent insulinotropic polypeptide (GIP) and apolipoprotein B48 were also investigated.

Results: Eighteen subjects with type 2 diabetes received one of three GLP-1RAs, i.e., lixisenatide, n = 7; liraglutide, n = 6; or dulaglutide, n = 5. While 12-week administration of all of the GLP-1RAs significantly reduced HbA1c, only lixisenatide and liraglutide, but not dulaglutide, significantly reduced body weight. Postprandial glucose elevation was improved by all of the GLP-1RAs. Postprandial insulin levels were suppressed by lixisenatide, while insulin levels were enhanced by liraglutide. Postprandial glucagon levels were suppressed by lixisenatide. The gastric emptying rate was significantly delayed by lixisenatide, while liraglutide and dulaglutide had limited effects on gastric emptying. GIP secretion was suppressed by lixisenatide and liraglutide. Apolipoprotein B48 secretion was suppressed by all of the GLP-1RAs.

Conclusions: All of the GLP-1RAs were found to improve HbA1c in a 12-week prospective observational study in Japanese individuals with type 2 diabetes. However, differences in the mechanisms of the glucose-lowering effects and body weight reduction were observed.

Citing Articles

Sequence of Eating at Japanese-Style Set Meals Improves Postprandial Glycemic Elevation in Healthy People.

Kurotobi Y, Kuwata H, Matsushiro M, Omori Y, Imura M, Nakatani S Nutrients. 2025; 17(4).

PMID: 40004986 PMC: 11858527. DOI: 10.3390/nu17040658.

Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: a multidisciplinary consensus statement: A consensus....

El-Boghdadly K, Dhesi J, Fabb P, Levy N, Lobo D, McKechnie A Anaesthesia. 2025; 80(4):412-424.

PMID: 39781571 PMC: 11885194. DOI: 10.1111/anae.16541.

Differential effects of imeglimin and metformin on insulin and incretin secretion-An exploratory randomized controlled trial.

Usui R, Hamamoto Y, Imura M, Omori Y, Yamazaki Y, Kuwata H Diabetes Obes Metab. 2024; 27(2):856-865.

PMID: 39592886 PMC: 11701202. DOI: 10.1111/dom.16086.

Role of Point-of-Care Gastric Ultrasound in Advancing Perioperative Fasting Guidelines.

Razak A, Baburyan S, Lee E, Costa A, Bergese S Diagnostics (Basel). 2024; 14(21).

PMID: 39518332 PMC: 11545054. DOI: 10.3390/diagnostics14212366.

Confounding Factors in the Association Between Glucagon-Like Peptide-1 Receptor Agonist Use and Retained Gastric Contents in Asymptomatic Patients Undergoing Upper Gastrointestinal Endoscopy: A Retrospective Study.

Elimihele T, Mangrola A, Oshomoji O, Wilson N, Nnamani I, Ashong B Cureus. 2024; 16(9):e69152.

PMID: 39398811 PMC: 11467768. DOI: 10.7759/cureus.69152.

References

Jelsing J, Vrang N, Hansen G, Raun K, Tang-Christensen M, Knudsen L . Liraglutide: short-lived effect on gastric emptying -- long lasting effects on body weight. Diabetes Obes Metab. 2012; 14(6):531-8. DOI: 10.1111/j.1463-1326.2012.01557.x. View

Nauck M, Quast D, Wefers J, Meier J . GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2020; 46:101102. PMC: 8085572. DOI: 10.1016/j.molmet.2020.101102. View

Umapathysivam M, Lee M, Jones K, Annink C, Cousins C, Trahair L . Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes. 2013; 63(2):785-90. PMC: 3900552. DOI: 10.2337/db13-0893. View

Yabe D, Seino Y . Liraglutide in adults with type 2 diabetes: global perspective on safety, efficacy and patient preference. Clin Med Insights Endocrinol Diabetes. 2012; 4:47-62. PMC: 3411533. DOI: 10.4137/CMED.S5976. View

Amblee A . Dulaglutide for the treatment of type 2 diabetes. Drugs Today (Barc). 2014; 50(4):277-89. DOI: 10.1358/dot.2014.50.4.2132740. View

Creutzfeldt W, Talaulicar M, Ebert R, Willms B . Inhibition of gastric inhibitory polypeptide (GIP) release by insulin and glucose in juvenile diabetes. Diabetes. 1980; 29(2):140-5. DOI: 10.2337/diab.29.2.140. View

Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E . Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2014; 1(5):212-28. PMC: 4020724. DOI: 10.1111/j.2040-1124.2010.00074.x. View

Nagai Y, Hashimoto E, Oikawa R, Asai S, Terashima Y, Nakamura Y . Differing effects of liraglutide on gastric emptying in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2013; 16(6):573-6. DOI: 10.1111/dom.12247. View

Knudsen L, Secher A, Hecksher-Sorensen J, Pyke C . Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus. J Diabetes Investig. 2016; 7 Suppl 1:56-63. PMC: 4854506. DOI: 10.1111/jdi.12463. View

10.

Drucker D, Habener J, Holst J . Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest. 2017; 127(12):4217-4227. PMC: 5707151. DOI: 10.1172/JCI97233. View

11.

Shin A, Camilleri M . Diagnostic assessment of diabetic gastroparesis. Diabetes. 2013; 62(8):2667-73. PMC: 3717858. DOI: 10.2337/db12-1706. View

12.

Kapitza C, Forst T, Coester H, Poitiers F, Ruus P, Hincelin-Mery A . Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab. 2013; 15(7):642-9. PMC: 3752965. DOI: 10.1111/dom.12076. View

13.

Suganuma Y, Shimizu T, Sato T, Morii T, Fujita H, Sassa M . Magnitude of slowing gastric emptying by glucagon-like peptide-1 receptor agonists determines the amelioration of postprandial glucose excursion in Japanese patients with type 2 diabetes. J Diabetes Investig. 2019; 11(2):389-399. PMC: 7078094. DOI: 10.1111/jdi.13115. View

14.

Inoue M, Shiramoto M, Oura T, Nasu R, Nakano M, Takeuchi M . Effect of Once-Weekly Dulaglutide on Glucose Levels in Japanese Patients with Type 2 Diabetes: Findings from a Phase 4, Randomized Controlled Trial. Diabetes Ther. 2019; 10(3):1019-1027. PMC: 6531535. DOI: 10.1007/s13300-019-0605-7. View

15.

Sanaka M, Nakada K . Stable isotope breath tests for assessing gastric emptying: A comprehensive review. J Smooth Muscle Res. 2011; 46(6):267-80. DOI: 10.1540/jsmr.46.267. View

16.

Yabe D, Kuwata H, Seino Y . The journey to understanding incretin systems: Theory, practice and more theory. J Diabetes Investig. 2019; 10(5):1171-1173. PMC: 6717807. DOI: 10.1111/jdi.13123. View

17.

Sakurai K, Lee E, Morita A, Kimura S, Kawamura H, Kasamatsu A . Glucagon-like peptide-1 secretion by direct stimulation of L cells with luminal sugar vs non-nutritive sweetener. J Diabetes Investig. 2014; 3(2):156-63. PMC: 4020733. DOI: 10.1111/j.2040-1124.2011.00163.x. View

18.

Yabe D, Eto T, Shiramoto M, Irie S, Murotani K, Seino Y . Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial. Diabetes Obes Metab. 2016; 19(3):442-447. PMC: 5347937. DOI: 10.1111/dom.12817. View

19.

Hsieh J, Longuet C, BAKER C, Qin B, Federico L, Drucker D . The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia. 2009; 53(3):552-61. DOI: 10.1007/s00125-009-1611-5. View

20.

McCarty D, Coleman M, Boland C . Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management. Ann Pharmacother. 2017; 51(5):401-409. DOI: 10.1177/1060028017689878. View